Background: To investigate the value of positron emission tomography (PET) and PET/computed tomography (CT) using fluorine-18-fluorodeoxyglucose ( 18 F-FDG) in the diagnosis, staging, restaging and recurrence monitoring of Ewing sarcoma family of tumors (ESFTs), a meta-analysis was performed through systematically searching PubMed, Embase, and Cochrane Central library to retrieve articles.
Introduction
The Ewing sarcoma family of tumors (ESFT) includes a series of small, round-cell malignancies that are characterized by varying degrees of neuroectodermal differentiation. [1] Ewing sarcoma (ES) of bone is the most common type of ESFT and the second most common primary bone sarcoma in children and adolescents. [2, 3] Moreover, extra skeletal ES, Askin tumor (ES arising in the chest) and primitive neuroectodermal tumors (PNET) also belong to ESFT. [1] Combined therapy, including high-dose chemotherapy, surgery and/or radiotherapy, has dramatically improved the survival of localized ESFT. [4] Nevertheless, ESFTs have a tendency to distantly metastasize and locally relapse. Approximately 25% of ES cases have detectable metastases at presentation; on the other hand, approximately 30%∼40% of patients will develop local or distant recurrence after treatment, which would modify the outcome with a poor prognosis. [5] [6] [7] [8] Consequently, accurate initial staging, restaging and recurrence monitoring play a crucial role in the treatment strategy for ESFT. Traditional imaging modalities used to assess ESFT include plain film, computed tomography (CT), magnetic resonance imaging, bone marrow biopsy and aspiration, bone scintigraphy, and fluorine-18-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) or PET/CT. ESFT possess increased rate of glycolysis. After intravenous administration of 18 F-FDG, a labeled glucose analog, accumulates in the malignant cells of ESFT and is avidly retained. By detecting sites with high 18 F-FDG uptake, PET could identify malignant ESFT lesions. Hawkins et al [9] suggested that 18 F-FDG PET could be applied to assess the histological response of ESFT after treatment and thus predict the outcome. More recently, hybrid 18 F-FDG PET/CT further combined morphologic and metabolic information and achieved better diagnostic performance. Although guidelines proposed by National Comprehensive Cancer Network (NCCN) and the Children's Oncology Group Bone Tumor Committee both recommend 18 F-FDG PET as a considerable complementary tool after the diagnosis of ES, the optimal or standardized combination of staging tools is still unclear. [10, 11] Multiple trials have attempted to quantitatively measure the accuracy of 18 F-FDG PET and PET/CT in the diagnosis, staging and recurrence monitoring of ESFT, but their results are inconclusive. A previous meta-analysis suggested that 18 F-FDG PET and PET/CT have high pooled sensitivity and specificity (0.96 and 0.92, respectively) in diagnosing ESFT. However, this statistical analysis only included 5 studies and did not differentiate sites of metastatic lesions or assess the accuracy on lesion-based analysis. [12] Meanwhile, more eligible studies were published in recent years. To draw a more precise conclusion on this topic, a systematic review and meta-analysis were conducted systematically involving published studies.
Materials and methods
This investigation was conducted based on "the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)" statement. [14] Ethical approval and patient consent were not necessary, as the analysis was performed based on data available in published literature.
Article search and study selection
Previously published studies were collected using 2 approaches. First, PubMed, Embase and the Cochrane Library were systematically searched using the following keywords: 1) "Ewing" or "sarcoma" and 2) "PET" or "positron emission tomography".
No language or publication time limitation was imposed. The last search was updated on February 28, 2018. Subsequently, the bibliographies of relevant articles (reviews, editorials, included trials and meta-analyses) were screened by hand to retrieve additional studies.
Clinical studies appraising the performance of 18 F-FDG PET and PET/CT in the diagnosis, staging and recurrence monitoring of patients with ESFT were eligible for inclusion in the metaanalysis. The studies that provided data to calculate the sensitivity and specificity were further included in the statistical analysis. For articles containing overlapping data, the one presenting the most comprehensive data or that was published the most recently was chosen.
The exclusion criteria were as follows:
1) letters, reviews, editorials and other non-original articles; 2) trials with fewer than 5 patients with ESFT; 3) congress proceedings; and 4) animal experiment.
Two reviewers (LFX and ZQY) independently and repeatedly evaluated the retrieved articles using the aforementioned criteria. Ineligible articles were first excluded by screening titles and abstracts. Then, the full texts of remaining studies were downloaded and reviewed in detail.
Data extraction and quality assessment
To reduce the bias, 3 reviewers (LFX, ZQY, and DJL) independently performed this process. Any discrepancies were resolved by consensus. For each included trial, the following basic information was recorded: the first author's surname, year of publication, original country, study design, number, age and gender of participants, 18 A quality assessment tool for the diagnostic accuracy studies (QUADAS) was used to evaluate the methodological quality of the included studies. [13] This tool contains 14 items, and each one was described for 1 score. Any discrepancies were resolved by consensus from a third investigator (DJL).
Statistical analysis
All statistical analyses were performed with Meta-disc 1.4. The heterogeneity across studies was evaluated using I-square; for an I-square <50%, the between-study heterogeneity was considered not significant. To quantitatively assess the performance of 18 F-FDG PET or PET/CT in the diagnosis, staging and recurrence monitoring of ESFT, a random effect model was applied to calculate the following pooled outcome estimates: sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odd ratio (DOR) (with 95% confidence interval) on examination-based or lesion-based analysis. Moreover, the summary receiver operating characteristic curve (SROC) with sensitivity as the x-coordinate and 1-specificity as the y-coordinate was constructed. The Q * -index (the point where sensitivity and specificity are equal on SROC) and the area under SROC (AUC) could reflect the diagnostic accuracy of 18 F-FDG PET and PET/CT.
Results

Search results and study characteristics
The search of electronic databases and references yielded a total of 2007 titles and abstracts. After careful selection, 23 articles published in English were included in the meta-analysis. The detailed article search and study selection process were listed in Figure 1 . Several studies sharing overlapped participants presented data for different subgroup analyses. Therefore, all of these studies were included in our research. The extracted data were presented in Tables 1 and 2 . As for the methodological quality, the review authors' QUADAS judgments of included studies were presented in Figure 2 .
Lesion-based analysis
A total of 13 trials, [16, [18] [19] [20] 22, [25] [26] [27] [29] [30] [31] 34, 36] involving 689 lesions, were available to investigate the diagnostic performance of 18 F-FDG PET and PET/CT in ESFT. The pooled results were as follows: sensitivity of 86% (95% CI of 82%-89%), specificity of 80% (95% CI of 75%-85%), PLR of 3.92 (95% CI of 3.08-4.98), NLR of 0.19 (95% CI of 0.12-0.30) and DOR of 29.22 (95% CI of 16.49-51.78). There was no significant betweenstudy heterogeneity for the sensitivity (I-square = 0.001%). Meanwhile, the Q * -index and AUC were 0.8474 and 0.9147, respectively ( Fig. 3) . Meanwhile, 9 studies [16, [18] [19] [20] 22, [25] [26] [27] 35] involving a total of 170 ESFT described SUVmax uptake in the primary lesions at initial staging, all being 18 F-FDG-avid.
3.3. Examination-based analysis 3.3.1. Recurrence. A total of 5 trials [20, 23, 27, 31, 33] involving 123 examinations addressed ESFT recurrence (including local and distant recurrence) using 18 F-FDG PET or PET/CT. The threshold effect was found in the provided examination-based data (Spearman correlation coefficient = 0.895; P value = .040). The pooled results for 18 F-FDG PET and PET/CT to detect ESFT recurrence were as follows: sensitivity of 93% (95% CI of 83%-98%), specificity of 90% (95% CI of 80%-96%), PLR of 8.53 (95% CI of 4.12-17.65), NLR of 0.09 (95% CI of 0.04-0.21), and DOR of 109.98 (95% CI of 30.66-394.54). There was no significant between-study heterogeneity for the included outcome estimates (all I-squares = 0). Meanwhile, the Q * -index and AUC were 0.9129 and 0.9656, respectively (Fig. 4) .
Subgroup analysis was performed exclusively on the basis of PET/CT data. A total of 4 trials [23, 27, 31, 33] involving 106 examinations addressed ESFT recurrence using 18 F-FDG PET/ CT. The pooled results for 18 F-FDG PET to detect ESFT recurrence were as follows: sensitivity of 94% (95% CI of 83%-98%), specificity of 91% (95% CI of 80%-97%), PLR of 8.82 (95% CI of 4.00-19.45), NLR of 0.08 (95% CI of 0.03-0.22) and DOR of 128.49 (95%CI of 31.15-529.99). There was no significant between-study heterogeneity for the included outcome estimates (all I-squares = 0). Meanwhile, the Q * -index and AUC were 0.9198 and 0.9700, respectively (Fig. 5 ).
3.3.2. Lung metastasis. On the examination-based level, a total of 8 trials [5, 17, 23, 26, [29] [30] [31] 33] involving 278 examinations investigated lung metastasis of ESFT using 18 F-FDG PET or PET/CT. The pooled results for 18 F-FDG PET and PET/CT to detect ESFT recurrence were as follows: sensitivity of 72% (95% CI of 57%-84%), specificity of 97% (95% CI of 94%-99%), PLR of 13.51 (95% CI of 6.22-29.34), NLR of 0.38 (95% CI of 0.20-0.74) and DOR of 60.55 (95% CI of 14.41-254.39). There was no significant between-study heterogeneity for the included outcome estimates. The Q * -index and AUC were 0.8861 and 0.9467, respectively (Fig. 6) .
Subgroup analysis was also performed exclusively on the basis of PET/CT data. On the examination-based level, a total of 6 trials [5, 23, 26, 30, 31, 33] involving 189 examinations investigated lung metastasis of ESFT using 18 F-FDG PET/CT. The pooled Huang 18 F-FDG PET and PET/CT to detect ESFT recurrence were as follows: sensitivity of 82% (95% CI of 63%-94%), specificity of 98% (95% CI of 95%-100%), PLR of 32.04 (95% CI of 9.85-104.24), NLR of 0.24 (95% CI of 0.06-0.89) and DOR of 160.70 (95% CI of 30.68-841.61). There was no significant between-study heterogeneity for the included outcome estimates. The Q * -index and AUC were 0.9807 and 0.9972, respectively (Fig. 7) .
Bone metastasis.
A total of 6 trials [5, 15, 23, 26, 31, 33] involving 246 examinations addressed osseous metastasis of ESFT using 18 F-FDG PET or PET/CT. The pooled results for 18 F-FDG PET and PET/CT to detect bone metastasis of ESFT were as follows: sensitivity of 91% (95% CI of 80% to 97%), specificity of 98% (95% CI of 94%-99%), PLR of 26.60 (95% CI of 11.06-63.97), NLR of 0.15 (95% CI of 0.05-0.39) and DOR of 347.37 (95% CI of 78.50-1537.18). There was no significant between-study heterogeneity for the included outcome estimates. The Q * -index and AUC were 0.9492 and 0.9859, respectively (Fig. 8) .
Subgroup analysis was performed exclusively on the basis of PET/CT data. A total of 5 trials [5, 23, 26, 31, 33] involving 180 examinations addressed osseous metastasis of ESFT using 18 F-FDG PET/CT. The pooled results for 18 F-FDG PET and PET/CT (Fig. 9 ). There was no significant between-study heterogeneity for the included outcome estimates. The Q * -index and AUC were 0.9780 and 0.9965, respectively (Fig. 9 ).
3.3.4. Lymph metastasis. Only 6 studies [5, 23, 25, 26, 31, 33] involving 17 TP examinations and no FN examinations were included in this study. This result should be interpreted cautiously.
Discussion
Results of the diagnostic accuracy of 18 F-FDG PET and PET/CT in ESFT remain inconclusive. One previous study [37] tried to further clarify this issue, but none of the included studies specifically aimed at ESFT and did not statistically analyze the retrieved data. To the best of our knowledge, there is no metaanalysis comprehensively evaluating the performance of 18 F-FDG PET and PET/CT in the diagnosis, staging and recurrence monitoring of ESFT. In this meta-analysis, this issue was statistically investigated by analyzing data collected from 23 studies on the lesion-or examination-based level.
ESFT is rather rare. Approximately 225 cases of ESFT in patients younger than 20 years of age are diagnosed in North America annually. [38] No blood, urine or imaging tests can specifically identify ESFT, and the gold standard for diagnosing ESFT is still pathological examination. In 2000, Franzius et al first reported the value of PET in the diagnosis of Ewing's sarcoma. [15] On examination-based analysis, no FN cases and only 2 FP cases were observed (n = 66), and the sensitivity, specificity, and accuracy were 100%, 96%, and 97%, respectively. Previous studies suggested that the SUVmax of ESFT is normally high. [39] In our collected data, a total of 139 primary ESFT lesions retrieved from 8 studies were classified as 18 F-FDGavid. However, to be clear, as overlapping SUV exist in different sarcoma types, including benign lesions, 18 F-FDG PET and PET/ CT cannot distinctly differentiate between ESFT and other malignant tumors, and they are mainly used as staging tools.
Although the prognosis of ESFT has greatly improved, approximately 30%∼40% of patients will develop recurrent disease after treatment. The outcome of those patients is very poor and has an overall 5-year survival of less than 15%. [40, 41] Detecting patients with recurrence and improving the diagnostic accuracy at early stage may prompt effective treatment. For examination-based data, the high accuracy of 18 F-FDG PET and PET/CT for detecting recurrence (local or distant) of ESFT was demonstrated; the sensitivity, specificity, and DOR were 0.93, 0.90, and 109.98, respectively, which is similar to the conclusions for other recurrent malignant tumors. [42, 43] Especially, the sensitivity, specificity, and DOR of 18 F-FDG PET/CT solely for detecting recurrence (local or distant) of ESFT were 0.94, 0.91, and 128.49. 18 F-FDG PET/CT should be performed before a diagnostic biopsy site is chosen in patients with a high clinical suspicion of aggressive, advanced tumor. One retrospective study [44] involving 51 advanced lung cancer patients aimed to evaluate the safety and efficacy of 18 F-FDG PET/CT in bone metastases lesions. No serious complications were encountered, which demonstrated that PET/CT-guided percutaneous biopsy of 18 F-FDG-avid bone metastases is an effective and safe method that yields a high diagnostic success rate. Salem U and his co-authors reported that a high SUVmax of pre-therapeutic and post-therapeutic FDG PET/CT correlated with overall survival and that a pretherapeutic SUVmax >11.6 decreased the overall survival and progression-free survival in patients with ES. They revealed that 18 F-FDG PET/CT can be used as a prognostic indicator of survival in primary ES. [45] The most crucial indicator for an adverse prognosis of ESFT is the presence of metastatic disease. Approximately 25% of patients with ESFT already have detectable metastasis at diagnosis. Cotterill SJ et al analyzed 975 Ewing sarcoma patients from the European Intergroup Cooperative Group and observed that their survival rate had a good correlation with the number and location of metastatic lesions. [46] Therefore, the prognostic staging and restaging of ESFT plays a vital role in developing treatment plans and eventually ameliorates the outcome of patients. Although several imaging modalities, including chest CT, bone scintigraphy, 18 F-FDG PET, and PET/CT, are recommended in the guidelines, the best imaging strategy remains unclear. An advantage of 18 F-FDG PET and PET/CT is that they can be used to identify systematic metastasis. In this investigation, we further performed examination analyses according to the metastatic sites. Most metastatic ESFT lesions occur in lung. [38] Compared to patients with bone-only metastases or a combination of lung and bone metastasis, patients with lung involvement have a better prognosis. [46] Bone is the second most frequently involved site for metastatic ESFT lesions. [38] DOR, as an indicator of diagnostic accuracy, reflects the association between the relevant disease, and test results by calculating a single special ratio that combines the sensitivity and specificity. A higher DOR (range from 0 to infinity) stands for a more favorable diagnostic accuracy. In this respect, this meta-analysis revealed that diagnosing lung metastasis of ESFT using 18 F-FDG-PET and PET/CT does have a good accuracy with DORs of 60.55 (95% CI of 14.41-254.39) as for bone metastasis with DORs of 347.37 (95% CI of 78.50-1537.18). A similar trend was observed on SROC with AUCs of 0.9467 and 0.9859 for lung and bone metastases, respectively. Considering the high accuracy of 18 F-FDG PET and PET/CT in detecting the osseous metastasis of ESFT, bone scintigraphy may be omitted from the staging of ESFT. Metastasis to the bone marrow, lymph nodes, and other sites, although uncommon, is also observed in patients with ESFT. In retrieved patients, all metastatic lesions in lymph nodes were identified.
Several subgroup-analyses were made based exclusively on PET/CT data about diagnosis of recurrence, lung metastases, and osseous metastases. Although seemingly the results of PET/CT were better compared with PET, we could not draw a distinct conclusion due to the overlapping confidence intervals.
The reliability and innovation of this research rely on the large sample size, uniform statistical processing, and elaborate subgroup analysis, which will help us obtain a more comprehensive understanding of the performance of 18 F-FDG PET and PET/CT in the diagnosis, staging, and recurrence monitoring of ESFT. However, some limitations in this study merited consideration. First, this is a meta-analysis and systemic review; we analyzed the questions on the study level instead of on the patient level. Consequently, underestimation/overestimation was unavoidable. Second, there was methodological variability in the included trials, such as the method for measuring the 18 F-FDG uptake, cutoff for determining the lesion positivity, reference standards tests and duration of follow-up. In addition, some studies evaluated 18 F-FDG PET, while others evaluated PET/CT. Last but not least, several subgroup analyses were based on a small number of studies, which could reduce their power. We made our best effort to extract data on the sensitivity and specificity from 3 levels of analysis, but in some subgroups, sufficient data were unavailable for quantitative statistics.
Conclusion
In conclusion, this systemic review and meta-analysis indicated high sensitivity for 18 F-FDG PET and PET/CT in identifying primary ESFT lesions. Moreover, 18 F-FDG PET and PET/CT, with extremely high accuracy, could be considered valuable methods for detecting metastasis and post-operational recurrence, which might have a profound impact on the development of treatment protocols for ESFT. Nevertheless, considering the possibility of false-positive and false-negative cases, pathological examination or long-term follow-up should be performed for 18 F-FDG-avid ESFT lesions. Large-scale, randomized, prospective trials are still needed to further warrant conclusions. 
